One of the leading companies” Hindustan Laboratories Limited” got SEBI observations for IPO (Initial Public Offering).
As per the sources, the total issue size up to 1,41,00,000 equity shares of face value of ₹10 each. Further, the fresh issue of up to 50,00,000 equity shares and OFS up to 91,00,000 equity shares.
Hindustan Laboratories Promoter’s Details
Rajesh Vasantray Doshi, the promoter and selling shareholder, plans to sell up to 91,00,000 shares through the Offer for Sale (OFS).
IPO Fund Deployment
- The company will use the IPO funds for its working capital requirements.
- A portion of the funds will be used for general corporate purposes.
IPO Lead Managers & Registrar
The IPO has Choice Capital Advisors Private Limited as the book-running lead manager, while MUFG Intime India has been appointed as the registrar for the issue.
The company also plans to list its shares on both the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE).
Hindustan Laboratories Limited is a pharmaceutical firm in India. Moreover, it is engaged in the large-scale manufacturing and supply of generic medicines to government institutions under a business-to-government (B2G) framework.
Hindustan Laboratories IPO Prospectus:
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | To be Updated Soon |
Hindustan Laboratories Company Financial Report
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax |
| 2023 | ₹179.48 | ₹149.72 | ₹22.25 |
| 2024 | ₹194.33 | ₹148.25 | ₹34.14 |
| 2025 | ₹227.38 | ₹172.26 | ₹41.27 |
| Sep 2025 | ₹115.78 | ₹91.13 | ₹18.23 |
Hindustan Laboratories IPO Valuation – FY2025
Hindustan Laboratories IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| Earning Per Share (EPS): | ₹182.38(Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 26.11% |
| Net Asset Value (NAV): | ₹39.51 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Ajanta Pharma Limited | 73.56 | 35.25 | 25.02 | 301.59 | 777.90 Cr. |
| Syncom Formulations (India) Limited | 0.57 | 25.70 | 15.69 | 3.64 | 482.45 Cr. |
| Windlas Biotech Limited | 29.19 | 25.70 | 12.76 | 243.18 | 4742.60 Cr. |
Objects of the Issue
- Funding working capital requirement of our Company
- General Corporate Purposes
